Clinical Focus

  • Obstetrics and Gynecology

Academic Appointments

Honors & Awards

  • Outstanding Faculty Professor of Gynecology, Resident Staff of Stanford Obstetrics and Gynecology (2013-2014)
  • Administrative Chief Resident, UCLA Department of Obstetrics and Gynecology, Elected by Resident Staff (2012-2013)
  • Outstanding Resident Research Award, UCLA Department of Obstetrics and Gynecology (2012)
  • Alpha Omega Alpha Honor Medical Society, UCLA David Geffen School of Medicine (2009)

Boards, Advisory Committees, Professional Organizations

  • Member, American Congress of Obstetrics and Gynecology (ACOG) (2008 - Present)
  • Member, American Association of Gynecologic Laparoscopists (AAGL) (2012 - Present)

Professional Education

  • Bachelor of Science, UCLA, Microbiology, Immunology & Molecular Genetics (2004)
  • Residency:UCLA School of Medicine (2013) CA
  • Medical Education:UCLA School of Medicine (2009) CA

Research & Scholarship

Clinical Trials

  • Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor Recruiting

    Approximately 22% of term pregnancies are induced. Misoprostol, a prostaglandin E1 analogue, is a widely accepted induction agent, that has been proven safe and effective for induction of labor. It stimulates both cervical ripening and uterine contractions, thus making it an ideal induction agent for unfavorable cervices. Research has examined the pharmacokinetics of different administration routes and effects on uterine contractility, side effects, and safety. Vaginal misoprostol has been shown to be superior over oral administration however patients often prefer a more tolerable route. Buccal administration has already been shown to be as effective as vaginal misoprostol for cervical ripening and induction in both first trimester and second trimester abortions. There is minimal research comparing buccal versus vaginal for third trimester induction of labor. The investigators study is a prospective, double blinded, randomized control trial comparing vaginal misoprostol and buccal misoprostol in equal dosages of 25 mcg. The investigators seek to answer the question whether buccal misoprostol is as effective as vaginal misoprostol for third trimester induction of labor.

    View full details


Journal Articles

  • Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Annals of the New York Academy of Sciences Wilson, L. L., Tran, L., Morton, D. L., Hoon, D. S. 2004; 1022: 317-22


    Tumor progression is a dynamic sequence of events that involves specific protein changes. We hypothesized that Surface Enhanced Laser Desorption/Ionization (SELDI) mass spectrometric analysis of sera from patients with AJCC stage I and II melanoma with negative loco-regional lymph nodes could identify potential melanoma-associated protein biomarkers of disease recurrence. Serum specimens were collected from 49 patients who developed recurrence (n = 25) or remained free of recurrence (n = 24) without evidence of disease following complete resection (AJCC stage I and II). Follow-up was longer than 5 years. Serum proteins were denatured and applied onto two protein chip chemistry surfaces (weak cationic WCX2; metal-binding, IMAC3-Cu). SELDI ProteinChip mass spectrometry was then performed. SELDI data were analyzed, protein peak clustering and classification were performed, and a supervised classification algorithm was employed to classify the dataset. Multiple protein peaks ranging from 3.3 to 30 kDa were identified between patients with recurrence and those without recurrence, and the expression pattern differences of three proteins were used to generate the discriminating classification tree. The biomarkers were expressed with a high degree of reproducibility. In this early characterization study, melanoma recurrence was predicted with a sensitivity of 72% (18/25) and a specificity of 75% (18/24). This novel pilot study revealed three proteins that accurately identified patients who developed recurrence after curative resection of primary melanoma.

    View details for DOI 10.1196/annals.1318.047

    View details for PubMedID 15251977


  • Buccal versus vaginal misoprostol in third trimester induction of labor

    Preliminary data presented

    Time Period


    Presented To

    68th Annual Ob/Gyn Assembly of Southern California


    Los Angeles, CA

Stanford Medicine Resources: